Precocious puberty, gonadotropin-dependent

Precocious Puberty, Gonadotropin-Dependent

Precocious puberty, gonadotropin-dependent, also known as central precocious puberty (CPP), is a condition characterized by the early onset of puberty due to the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis. This condition results in the early development of secondary sexual characteristics and accelerated growth and bone maturation.

Pathophysiology

Central precocious puberty is caused by the early release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This hormone stimulates the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the gonads (ovaries in girls and testes in boys) to produce sex steroids such as estrogen and testosterone. These sex steroids are responsible for the development of secondary sexual characteristics.

Epidemiology

CPP is more common in girls than in boys, with a female-to-male ratio of approximately 10:1. The condition is considered precocious if it occurs before the age of 8 in girls and before the age of 9 in boys.

Clinical Presentation

Children with CPP present with early development of secondary sexual characteristics. In girls, this includes breast development (thelarche), pubic hair growth (pubarche), and the onset of menstruation (menarche). In boys, signs include testicular enlargement, pubic hair growth, and increased penile size.

Diagnosis

The diagnosis of CPP is based on clinical evaluation, laboratory tests, and imaging studies. Key diagnostic steps include:

• Clinical Assessment: Evaluation of growth patterns and development of secondary sexual characteristics.
• Hormonal Tests: Measurement of LH, FSH, and sex steroid levels. A GnRH stimulation test may be performed to confirm the diagnosis.
• Imaging: A bone age assessment via X-ray can determine if bone maturation is advanced. An MRI of the brain may be conducted to rule out central nervous system abnormalities.

Treatment

The primary goal of treatment is to halt the progression of puberty and preserve adult height potential. Treatment options include:

• GnRH Analogues: These medications, such as leuprolide acetate, act as GnRH agonists to suppress the premature activation of the HPG axis.
• Monitoring: Regular follow-up is necessary to assess growth, development, and treatment efficacy.

Prognosis

With appropriate treatment, children with CPP can achieve normal adult height and development. Early diagnosis and intervention are crucial to prevent complications such as short stature and psychosocial issues.

Also see

• Hypothalamic-pituitary-gonadal axis
• Puberty
• Gonadotropin-releasing hormone
• Luteinizing hormone
• Follicle-stimulating hormone

Pediatric glossary of terms | Glossary of medical terms | Dictionary of pediatrics